270 related articles for article (PubMed ID: 27423464)
1. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma.
Lu A; Pallero MA; Lei W; Hong H; Yang Y; Suto MJ; Murphy-Ullrich JE
Am J Pathol; 2016 Mar; 186(3):678-90. PubMed ID: 26801735
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo.
Edwards JR; Nyman JS; Lwin ST; Moore MM; Esparza J; O'Quinn EC; Hart AJ; Biswas S; Patil CA; Lonning S; Mahadevan-Jansen A; Mundy GR
J Bone Miner Res; 2010 Nov; 25(11):2419-26. PubMed ID: 20499365
[TBL] [Abstract][Full Text] [Related]
4. TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model.
Green AC; Lath D; Hudson K; Walkley B; Down JM; Owen R; Evans HR; Paton-Hough J; Reilly GC; Lawson MA; Chantry AD
J Bone Miner Res; 2019 Dec; 34(12):2311-2326. PubMed ID: 31442332
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; Vande Broek I; De Raeve H; Coulton L; Van Camp B; Croucher P; Vanderkerken K
Cancer Res; 2009 Jul; 69(13):5307-11. PubMed ID: 19531653
[TBL] [Abstract][Full Text] [Related]
6. A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease.
Ji B; Genever PG; Fagan MJ
Int J Numer Method Biomed Eng; 2016 Mar; 32(3):e02735. PubMed ID: 26198466
[TBL] [Abstract][Full Text] [Related]
7. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
Edwards CM; Edwards JR; Lwin ST; Esparza J; Oyajobi BO; McCluskey B; Munoz S; Grubbs B; Mundy GR
Blood; 2008 Mar; 111(5):2833-42. PubMed ID: 18094333
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of TGF-β Signaling Attenuates Disuse-induced Trabecular Bone Loss After Spinal Cord Injury in Male Mice.
Sahbani K; Cardozo CP; Bauman WA; Tawfeek HA
Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34791098
[TBL] [Abstract][Full Text] [Related]
9. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.
Delgado-Calle J; Anderson J; Cregor MD; Condon KW; Kuhstoss SA; Plotkin LI; Bellido T; Roodman GD
Leukemia; 2017 Dec; 31(12):2686-2694. PubMed ID: 28529307
[TBL] [Abstract][Full Text] [Related]
10. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
[TBL] [Abstract][Full Text] [Related]
11. Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models.
Paton-Hough J; Tazzyman S; Evans H; Lath D; Down JM; Green AC; Snowden JA; Chantry AD; Lawson MA
J Bone Miner Res; 2019 May; 34(5):783-796. PubMed ID: 30320927
[TBL] [Abstract][Full Text] [Related]
12. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
14. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
[TBL] [Abstract][Full Text] [Related]
16. The effects of bortezomib on bone disease in patients with multiple myeloma.
Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated TGF-β signaling alters bone microstructure in a mouse model of Loeys-Dietz syndrome.
Dewan AK; Tomlinson RE; Mitchell S; Goh BC; Yung RM; Kumar S; Tan EW; Faugere MC; Dietz HC; Clemens TL; Sponseller PD
J Orthop Res; 2015 Oct; 33(10):1447-54. PubMed ID: 26173585
[TBL] [Abstract][Full Text] [Related]
18. Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner.
Buenrostro D; Kwakwa KA; Putnam NE; Merkel AR; Johnson JR; Cassat JE; Sterling JA
Bone; 2018 Aug; 113():77-88. PubMed ID: 29753718
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
Gooding S; Olechnowicz SWZ; Morris EV; Armitage AE; Arezes J; Frost J; Repapi E; Edwards JR; Ashley N; Waugh C; Gray N; Martinez-Hackert E; Lim PJ; Pasricha SR; Knowles H; Mead AJ; Ramasamy K; Drakesmith H; Edwards CM
Nat Commun; 2019 Oct; 10(1):4533. PubMed ID: 31586071
[TBL] [Abstract][Full Text] [Related]
20. TGF-β-related mechanisms of bone destruction in multiple myeloma.
Matsumoto T; Abe M
Bone; 2011 Jan; 48(1):129-34. PubMed ID: 20570621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
